Results 141 to 150 of about 8,597,475 (170)
Some of the next articles are maybe not open access.
Cost analysis of aflibercept 8 mg versus other anti-VEGF agents
Russian Annals of OphthalmologyPurpose. This study aimed to assess the economic impact of aflibercept 8 mg (114.3 mg/ml, 0.263 ml; hereinafter aflibercept 8 mg) compared with alternative anti-VEGF agents in adult patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) over a 2-year treatment period. Material and methods.
F.E. Shadrichev, Yu.V. Strunina
openaire +1 more source
Japanese Journal of Ophthalmology
To assess the effect of increased injection volume on intraocular pressure (IOP) following intravitreal injections of aflibercept 8 mg (70 µl) compared to conventional anti-vascular endothelial growth factor drugs.Retrospective observational study METHODS: This retrospective observational study included eyes treated with 50 µl of either aflibercept 2 ...
Xien Lu +6 more
openaire +2 more sources
To assess the effect of increased injection volume on intraocular pressure (IOP) following intravitreal injections of aflibercept 8 mg (70 µl) compared to conventional anti-vascular endothelial growth factor drugs.Retrospective observational study METHODS: This retrospective observational study included eyes treated with 50 µl of either aflibercept 2 ...
Xien Lu +6 more
openaire +2 more sources
Efficacy of 2 mg vs. High-Dose 8 mg Aflibercept in Neovascular Age Related Macular Degeneration
Klinische Monatsblätter für AugenheilkundeAbstract Purpose To investigate the efficacy of switching treatment from 2 mg aflibercept to high-dose 8 mg aflibercept in neovascular age-related macular degeneration (nAMD). Methods The database was screened for eyes with nAMD switched from 2 mg to 8 mg aflibercept.
Caspar Liesenhoff +11 more
openaire +1 more source
Ocular Immunology and Inflammation
To evaluate the risk of retinal vasculitis and related adverse events (AEs) among five commercially available anti-vascular endothelial growth factor (anti-VEGF) agents using data from the FDA Adverse Event Reporting System (FAERS).A retrospective pharmacovigilance study was conducted using FAERS data from Q1 2004 to Q4 2024.
M Hossein, Nowroozzadeh +1 more
openaire +2 more sources
To evaluate the risk of retinal vasculitis and related adverse events (AEs) among five commercially available anti-vascular endothelial growth factor (anti-VEGF) agents using data from the FDA Adverse Event Reporting System (FAERS).A retrospective pharmacovigilance study was conducted using FAERS data from Q1 2004 to Q4 2024.
M Hossein, Nowroozzadeh +1 more
openaire +2 more sources
Ophthalmic Surgery, Lasers and Imaging Retina
Background and Objective To assess the efficacy of intravitreal aflibercept 8 mg in treating neovascular age-related macular degeneration (nAMD) in patients previously treated with faricimab. Patients and Methods A retrospective study was conducted on nAMD patients with suboptimal ...
Bita, Momenaei +4 more
openaire +2 more sources
Background and Objective To assess the efficacy of intravitreal aflibercept 8 mg in treating neovascular age-related macular degeneration (nAMD) in patients previously treated with faricimab. Patients and Methods A retrospective study was conducted on nAMD patients with suboptimal ...
Bita, Momenaei +4 more
openaire +2 more sources
Japanese Journal of Ophthalmology
To investigate the efficacy and safety of loading phase treatment with 3 monthly intravitreal injections of aflibercept 8 mg for neovascular age-related macular degeneration (nAMD).Retrospective, interventional case series.We retrospectively analyzed 83 consecutive eyes of 80 patients with treatment-naïve nAMD who received 3 monthly injections of ...
Hidetaka Matsumoto +4 more
openaire +2 more sources
To investigate the efficacy and safety of loading phase treatment with 3 monthly intravitreal injections of aflibercept 8 mg for neovascular age-related macular degeneration (nAMD).Retrospective, interventional case series.We retrospectively analyzed 83 consecutive eyes of 80 patients with treatment-naïve nAMD who received 3 monthly injections of ...
Hidetaka Matsumoto +4 more
openaire +2 more sources
Graefe's Archive for Clinical and Experimental Ophthalmology
Areum Jeong, Seung Chul Baek, Min Sagong
openaire +1 more source
Areum Jeong, Seung Chul Baek, Min Sagong
openaire +1 more source